Khalife Ghida, Waris Juho, Bødtger Uffe, Isaksson Johan, Neumann Kirill, Harðardóttir Hrönn, Andersén Heidi, Jekunen Antti, Lovén Maria, Vasankari Tuula, Nurmi-Rantala Susanna, Torkki Paulus
Department of Public Health, University of Helsinki, Helsinki, Finland.
Respiratory Research Unit PLUZ, Department of Internal and Respiratory Medicine, Zealand University, Hospital Roskilde & Nastved, Næstved, Denmark; Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.
Acta Oncol. 2025 Jun 4;64:734-741. doi: 10.2340/1651-226X.2025.42778.
Lung cancer (LC) is the leading cause of cancer-related deaths worldwide. Despite societal, economic and genetic similarities, 5-year age-standardized relative survival rate is lower in Finland compared to the other Nordic countries. Previous studies have identified discrepancies in LC guidelines, but research on actual care practices remains limited. We aim to address this knowledge gap by conducting a comprehensive examination of the current care practices for LC patients in the Nordic countries.
We employed a non-interventional, prospective study design. We conducted an expert workshop involving LC specialists from Finland to formulate relevant questions for a structured survey. This survey was distributed to healthcare professionals (HCPs) across Nordic hospitals and primary care units. The survey results were then analyzed, and a follow-up Nordic LC expert workshop was held to identify the most relevant factors potentially influencing LC survival outcomes.
Four key differences in care practices between Finland and other Nordic countries were identified: (1) resources available in primary care units, (2) waiting times in primary care, (3) availability of novel treatments and (4) tracking of LC survival and mortality outcomes by the hospital. Finland has the lowest access to computed tomography (CT) from primary care, longest waiting times in primary care, and lacks a national outcome tracking system. Some medical doctors in Finland and Iceland highlighted observed limitations in specific cases involving access to neoadjuvant immunotherapy and chemotherapy.
Several factors unrelated to specialized LC care are likely contributing to poorer 5-year survival rates for LC in Finland. These findings may be applicable to other healthcare systems as well.
肺癌是全球癌症相关死亡的主要原因。尽管在社会、经济和基因方面存在相似性,但与其他北欧国家相比,芬兰的5年年龄标准化相对生存率较低。先前的研究已经发现肺癌指南存在差异,但关于实际护理实践的研究仍然有限。我们旨在通过全面审视北欧国家肺癌患者的当前护理实践来填补这一知识空白。
我们采用了非干预性前瞻性研究设计。我们举办了一次专家研讨会,邀请来自芬兰的肺癌专家为结构化调查制定相关问题。该调查被分发给北欧各医院和基层医疗单位的医疗保健专业人员(HCPs)。然后对调查结果进行分析,并举办了一次后续的北欧肺癌专家研讨会,以确定可能影响肺癌生存结果的最相关因素。
确定了芬兰与其他北欧国家在护理实践方面的四个关键差异:(1)基层医疗单位可用资源,(2)基层医疗的等待时间,(3)新型治疗方法的可及性,以及(4)医院对肺癌生存和死亡结果的追踪。芬兰从基层医疗获取计算机断层扫描(CT)的机会最少,基层医疗的等待时间最长,并且缺乏全国性的结果追踪系统。芬兰和冰岛的一些医生强调了在涉及新辅助免疫疗法和化疗可及性的特定案例中观察到的局限性。
一些与肺癌专科护理无关的因素可能导致芬兰肺癌患者的5年生存率较低。这些发现可能也适用于其他医疗系统。